Financhill
Sell
23

PALI Quote, Financials, Valuation and Earnings

Last price:
$0.78
Seasonality move :
-19.51%
Day range:
$0.75 - $0.79
52-week range:
$0.60 - $4.89
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.71x
Volume:
120K
Avg. volume:
313.5K
1-year change:
-83.23%
Market cap:
$3.8M
Revenue:
$250K
EPS (TTM):
-$7.24

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PALI
Palisade Bio
-- -$0.55 -100% -83.43% $10.67
ATNM
Actinium Pharmaceuticals
-- -$0.35 -100% -7.24% $5.00
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- $1.00
TOVX
Theriva Biologics
-- -$0.47 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PALI
Palisade Bio
$0.75 $10.67 $3.8M -- $0.00 0% --
ATNM
Actinium Pharmaceuticals
$1.52 $5.00 $47.4M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.69 $0.85 $4M -- $0.00 0% 0.16x
NNVC
Nanoviricides
$1.40 -- $22.4M -- $0.00 0% --
OGEN
Oragenics
$1.42 $1.00 $1M -- $0.00 0% 0.45x
TOVX
Theriva Biologics
$0.50 $7.00 $4.1M -- $0.00 0% 0.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PALI
Palisade Bio
-- 1.615 -- --
ATNM
Actinium Pharmaceuticals
-- -3.037 -- 9.03x
NBY
NovaBay Pharmaceuticals
4.54% -0.044 1.51% 0.75x
NNVC
Nanoviricides
-- -0.318 -- --
OGEN
Oragenics
-- 0.068 -- --
TOVX
Theriva Biologics
-- -3.388 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PALI
Palisade Bio
-- -$2.3M -- -- -- -$2.3M
ATNM
Actinium Pharmaceuticals
-- -$16.6M -95.08% -95.08% -12769.14% -$7.6M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
NNVC
Nanoviricides
-- -$2.2M -- -- -- -$2M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

Palisade Bio vs. Competitors

  • Which has Higher Returns PALI or ATNM?

    Actinium Pharmaceuticals has a net margin of -- compared to Palisade Bio's net margin of -11511.11%. Palisade Bio's return on equity of -- beat Actinium Pharmaceuticals's return on equity of -95.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    PALI
    Palisade Bio
    -- -$0.47 --
    ATNM
    Actinium Pharmaceuticals
    -- -$0.51 $36.4M
  • What do Analysts Say About PALI or ATNM?

    Palisade Bio has a consensus price target of $10.67, signalling upside risk potential of 1316.56%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 228.95%. Given that Palisade Bio has higher upside potential than Actinium Pharmaceuticals, analysts believe Palisade Bio is more attractive than Actinium Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    PALI
    Palisade Bio
    2 0 0
    ATNM
    Actinium Pharmaceuticals
    2 1 0
  • Is PALI or ATNM More Risky?

    Palisade Bio has a beta of 1.359, which suggesting that the stock is 35.867% more volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.325, suggesting its less volatile than the S&P 500 by 132.486%.

  • Which is a Better Dividend Stock PALI or ATNM?

    Palisade Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palisade Bio pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PALI or ATNM?

    Palisade Bio quarterly revenues are --, which are smaller than Actinium Pharmaceuticals quarterly revenues of $81K. Palisade Bio's net income of -$2.2M is higher than Actinium Pharmaceuticals's net income of -$15.9M. Notably, Palisade Bio's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palisade Bio is -- versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PALI
    Palisade Bio
    -- -- -- -$2.2M
    ATNM
    Actinium Pharmaceuticals
    -- -- $81K -$15.9M
  • Which has Higher Returns PALI or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to Palisade Bio's net margin of -49.65%. Palisade Bio's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    PALI
    Palisade Bio
    -- -$0.47 --
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About PALI or NBY?

    Palisade Bio has a consensus price target of $10.67, signalling upside risk potential of 1316.56%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 22.83%. Given that Palisade Bio has higher upside potential than NovaBay Pharmaceuticals, analysts believe Palisade Bio is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    PALI
    Palisade Bio
    2 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is PALI or NBY More Risky?

    Palisade Bio has a beta of 1.359, which suggesting that the stock is 35.867% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

  • Which is a Better Dividend Stock PALI or NBY?

    Palisade Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palisade Bio pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PALI or NBY?

    Palisade Bio quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Palisade Bio's net income of -$2.2M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Palisade Bio's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palisade Bio is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PALI
    Palisade Bio
    -- -- -- -$2.2M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns PALI or NNVC?

    Nanoviricides has a net margin of -- compared to Palisade Bio's net margin of --. Palisade Bio's return on equity of -- beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PALI
    Palisade Bio
    -- -$0.47 --
    NNVC
    Nanoviricides
    -- -$0.14 --
  • What do Analysts Say About PALI or NNVC?

    Palisade Bio has a consensus price target of $10.67, signalling upside risk potential of 1316.56%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 365.95%. Given that Palisade Bio has higher upside potential than Nanoviricides, analysts believe Palisade Bio is more attractive than Nanoviricides.

    Company Buy Ratings Hold Ratings Sell Ratings
    PALI
    Palisade Bio
    2 0 0
    NNVC
    Nanoviricides
    0 0 0
  • Is PALI or NNVC More Risky?

    Palisade Bio has a beta of 1.359, which suggesting that the stock is 35.867% more volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.

  • Which is a Better Dividend Stock PALI or NNVC?

    Palisade Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palisade Bio pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PALI or NNVC?

    Palisade Bio quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Palisade Bio's net income of -$2.2M is lower than Nanoviricides's net income of -$2.2M. Notably, Palisade Bio's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palisade Bio is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PALI
    Palisade Bio
    -- -- -- -$2.2M
    NNVC
    Nanoviricides
    -- -- -- -$2.2M
  • Which has Higher Returns PALI or OGEN?

    Oragenics has a net margin of -- compared to Palisade Bio's net margin of --. Palisade Bio's return on equity of -- beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PALI
    Palisade Bio
    -- -$0.47 --
    OGEN
    Oragenics
    -- -$3.60 --
  • What do Analysts Say About PALI or OGEN?

    Palisade Bio has a consensus price target of $10.67, signalling upside risk potential of 1316.56%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Oragenics has higher upside potential than Palisade Bio, analysts believe Oragenics is more attractive than Palisade Bio.

    Company Buy Ratings Hold Ratings Sell Ratings
    PALI
    Palisade Bio
    2 0 0
    OGEN
    Oragenics
    0 1 0
  • Is PALI or OGEN More Risky?

    Palisade Bio has a beta of 1.359, which suggesting that the stock is 35.867% more volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

  • Which is a Better Dividend Stock PALI or OGEN?

    Palisade Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palisade Bio pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PALI or OGEN?

    Palisade Bio quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Palisade Bio's net income of -$2.2M is lower than Oragenics's net income of -$2.2M. Notably, Palisade Bio's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palisade Bio is -- versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PALI
    Palisade Bio
    -- -- -- -$2.2M
    OGEN
    Oragenics
    0.45x -- -- -$2.2M
  • Which has Higher Returns PALI or TOVX?

    Theriva Biologics has a net margin of -- compared to Palisade Bio's net margin of --. Palisade Bio's return on equity of -- beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PALI
    Palisade Bio
    -- -$0.47 --
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About PALI or TOVX?

    Palisade Bio has a consensus price target of $10.67, signalling upside risk potential of 1316.56%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1294.42%. Given that Palisade Bio has higher upside potential than Theriva Biologics, analysts believe Palisade Bio is more attractive than Theriva Biologics.

    Company Buy Ratings Hold Ratings Sell Ratings
    PALI
    Palisade Bio
    2 0 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is PALI or TOVX More Risky?

    Palisade Bio has a beta of 1.359, which suggesting that the stock is 35.867% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

  • Which is a Better Dividend Stock PALI or TOVX?

    Palisade Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Palisade Bio pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PALI or TOVX?

    Palisade Bio quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Palisade Bio's net income of -$2.2M is higher than Theriva Biologics's net income of -$4.3M. Notably, Palisade Bio's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Palisade Bio is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PALI
    Palisade Bio
    -- -- -- -$2.2M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Microsoft Be a $5 Trillion Stock?
Will Microsoft Be a $5 Trillion Stock?

Microsoft’s market capitalization sits near $3.73 trillion today. To clear the…

Where Will C3.ai Stock Be in 1 Year?
Where Will C3.ai Stock Be in 1 Year?

C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…

What Is the Ceiling for IONQ Stock?
What Is the Ceiling for IONQ Stock?

IonQ (NYSE:IONQ) is a quantum computing startup that, like many…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 12

MiNK Therapeutics [INKT] is up 727.94% over the past day.

Buy
51
NEGG alert for Jul 12

Newegg Commerce [NEGG] is up 74.03% over the past day.

Buy
68
ATRO alert for Jul 12

Astronics [ATRO] is up 16.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock